PODCASTSign up to Get FREE Steroids, Sarma, Peptides eBooks
Muchas personas no sólo luchan por perder peso sino que también tienen problemas al intentar dejar de fumar. Afortunadamente, a single drug called Acomplia could solve both problems.
Hay una larga lista de alimentos que los culturistas y otros atletas tratan de evitar. Entre ellas se encuentran las comidas rápidas, aperitivos de engorde, y las bebidas azucaradas como el consumo a largo plazo o excesivo de este tipo de alimentos pueden dejar a una persona con sobrepeso y forzada para hacer frente a múltiples problemas de salud. Pero comer cosas como esta es a menudo un hábito desagradable que algunos atletas no se parecen a temblar sin importar lo difícil.
Fumar un hábito aún más desagradable que los atletas pueden caer es que podría ser aún más perjudicial para las metas físicas. Fumar conduce a aumento de la presión arterial y frecuencia cardíaca así como varias enfermedades de pulmón y nada de esto se suma a mejorar el cuerpo. Obviamente, la combinación de alimentos grasos y fumar equivale a una disminución en el rendimiento deportivo.
Así que los atletas y personas por igual necesitan a menudo hacia varias drogas para frenar los efectos desastrosos que pueden crear tales hábitos. Desafortunadamente, Esto quiere decir que tienen que tomar un medicamento de dieta y un medicamento de cesación de fumar por separado para satisfacer tanto necesidades. But imagine if there was a drug that could satisfy the two demands. No longer would people be required to take multiple medications in order to keep their weight down and their nicotine cravings in check.
You may not have to simply imagine this anymore though as the company Sanofi-Aventis believes that they may have developed a single drug that can act as both a dieting agent and smoking cessation agent. Its name is Acomplia and it has been the buzz of the pharmaceutical community as of late. This is mainly because it has been touted as more than just another diet pill with its proposed benefits to those who are trying to stop smoking.
The drug is said to work by blocking the receptors of a substance called cannabinoid 1. Encuentra un lugar prominente en el tejido graso en todo el cuerpo, cannabinoide 1 (CB 1) es la sustancia que es más responsable de estimular el hambre y otros antojos en el cerebro. Since Acomplia, a.k.a. Rimonabant, trabaja para suprimir el CB1 de causar ansiedad en el cerebro, it is also believed to help prevent people from overeating or smoking heavily.
Results from previous clinical trials have backed up many of the claims made by Sanofi-Aventis about its possible blockbuster drug Acomplia. En un par de ensayos llamado RIO: Europa y el RIO: AMÉRICA DEL NORTE, almost one-third of the patients participating in the two year procedure had a weight reduction of 10% al final de los ensayos. Circunferencia de la cintura también fue atenuada por una friolera 3 pulgadas en ambos de los estudios, así.
And these aren’t the only benefits that patients of the trials experienced either as all of those taking part in the clinical studies had higher levels of the good cholesterol, HDL. Los aspectos positivos no se detuvo aquí como todo el mundo parece mostrar una disminución en los triglicéridos (niveles altos pueden conducir a enfermedades del corazón) y una mejor sensibilidad a la insulina.
But the results of the trials weren’t all rosy though as there were some reported side effects too. Algunos de los más leves fueron náuseas, dolor en las articulaciones, mareo, diarrea, y los vómitos. No obstante, these effects were reported to have decreased during the second year of use with the drug. The major side effect came in the form of psychiatric problems, especially depression, derivados de uso discontinuado de la droga. It was even reported that some of the patients’ weights increased along with their psychiatric problems after their use of Rimonabant ended.
These side effects certainly remain question marks as to how well the drug will sell but its approval as a diet aid is no longer in question as Acomplia is already being sold in the United Kingdom. It has also received approval from the Food and Drug Administration for the sale in the United States and will be hitting the shelves sometime in the near future (posiblemente bajo el nombre de Zimulti en Estados Unidos. as opposed to its brand name of Acomplia in Europe).
While Acomplia’s ride to approval as a diet drug may have been fairly easy, en cuanto a conseguir por rigurosas normas de la FDA va, su aprobación como una ayuda para dejar de fumar fumar ha cumplido con nada más que polémica. The drug that was once dubbed as being able to double the odds of helping people to put down cigars and cigarettes somehow failed to live up to its own boasts in the eyes of the FDA as they rejected its use as a smoking cessation aid.
Sanofi-Aventis was shocked to say the least after the rejection of their prized Rimonabant as a smoking suppressor. Two trials failed to sway the FDA’s opinion of Acomplia and the decision was made in February to put a halt to one half of the dream drug’s marketability. If Sanofi-Aventis hopes for Rimonabant to ever become a smoking cessation aid, they will have to conduct another trial that can prove once and for all that the drug is an effective aid to those wishing to break the habit.
A pesar de su aprobación para dejar de fumar está en el limbo, Rimonabant hasn’t lost its momentum in the media and continues to create excitement among those wishing to shed some pounds. Acomplia has already been said to help those with diabetes in addition to keeping people’s weight down while they are on anti-depressants.
además, las últimas noticias sobre las drogas son que pueden jugar un papel en la lucha contra el cáncer de mama en las mujeres. This was reported after some tests were performed on mice by Italian researchers that revealed Acomplia inhibited the growth of a highly dangerous form of breast cancer called MBA-MB-231.
Plus the price of Rimonabant is currently lower in the United Kingdom than what was expected, providing an even bigger push to Sanofi-Aventis’ goal of selling 5 billion dollars-worth of Acomplia/Zimulti each year. Ha estado vendiendo durante todo 55 libras en Gran Bretaña (acerca de $100 EE.UU.) y es una de las drogas de dieta más baratas en el mercado a partir de ahora.
It’s still up in the air as to whether Rimonabant will hit the United States market under the name Acomplia or Zimulti but it is already clear that the drug’s arrival is anxiously awaited. Nuevos beneficios derivados del uso de Rimonabant están apareciendo constantemente en la vida cotidiana encabezados parece y la perspectiva de perder 10% of one’s body weight in one year already has people rushing to buy it illegally online.
A pesar del jurado sigue siendo hacia fuera en sus beneficios de dejar de fumar, many people already swear by Acomplia and the crowd just keeps growing. Is Rimonabant the end to the world’s (especialmente de América.) luchar contra la obesidad? El jurado está todavía fuera de esto así pero creo que muchas personas en todo el mundo están dispuestas a darle una oportunidad.
[Sc:signoff-std]
|
Además, disfrutarás de características importantes como:
 Leer más.... o Su calidad de miembro de la orden! |
la 5000 PM buzón - en lugar de 50, 
Sign up to Get FREE Steroids, Sarma, Peptides eBooks
